Tecan Group AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0012100191
CHF
125.30
-3.4 (-2.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Tecan Group AG stock-summary
stock-summary
Tecan Group AG
Pharmaceuticals & Biotechnology
Tecan Group AG is a Switzerland-based company engaged in the development, production and distribution of advanced automation and detection solutions for the life science laboratories. Its product portfolio is diversified into several product groups. The Liquid Handling & Robotics group encompasses laboratory technologies for safety, among others. The Reader & Washer product group covers micro plate instruments. The Microarray Products group includes microarray scanner and automated hybridization station. The HP D300 Digital Dispenser and Sample Management product groups cover systems for automated management of sample libraries. The Components group covers the supply services of products for laboratory automation instruments. The OEM (original equipment manufacturing) product group covers platform-based systems, systems from scratch and Cavro OEM Components. The Company also offers packaged software and consumables through Software and Consumables product groups, respectively.
Company Coordinates stock-summary
Company Details
Seestrasse 103 , MAENNEDORF None : 8708
stock-summary
Tel: 41 44 922811141 44 9228430
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Lukas Braunschweiler
Non-Executive Chairman of the Board
Mr. Heinrich Fischer
Non-Executive Vice Chairman of the Board
Mr. Lars Holmqvist
Non-Executive Director
Dr. Karen Huebscher
Non-Executive Director
Dr. Daniel Marshak
Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
110 Million
(Quarterly Results - Dec 2006)
Net Profit:
14 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 1,740 Million ()

stock-summary
P/E

81.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.21%

stock-summary
Debt Equity

-0.11

stock-summary
Return on Equity

1.80%

stock-summary
Price to Book

1.36